Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2025.03.030 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Michael D Chuong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida. Electronic address: munir@baptisthealth.net. Hauptthemen laut MEDLINE: Radiosurgery, Radiotherapy, Image-Guided, Magnetic Resonance Imaging. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViewRay Inc.
Abstract (Originalsprache)
PURPOSE: Stereotactic body radiation therapy (SBRT) is an advanced technique that enables precise delivery of radiation directly to a tumor, typically in ≤5 fractions. Single-fraction SBRT for visceral tumors is uncommon, likely related to concerns about risks of geographic tumor miss because of suboptimal cone beam computed tomography scan quality on conventional linear accelerators (linacs). Magnetic resonance (MR) guided linacs are a novel technology offering superior imaging that might facilitate the safe delivery of single-fraction SBRT. METHODS AND MATERIALS: We conducted a multicenter phase 2 trial of single-fraction SBRT delivered on a 0.35 Tesla MR-linac for primary or metastatic lesions of the lung (30-34 Gy; biologically effective dose [BED10] = 120-149.6 Gy10), liver (35-40 Gy; BED10 = 157.5-200 Gy10), pancreas (25 Gy; BED10 = 87.5 Gy10), adrenal gland (25 Gy10), kidney (25 Gy10), and abdominal/pelvic lymph nodes (25 Gy10). Primary objectives included feasibility and safety. The trial is registered with ClinicalTrials.gov, NCT04939246. RESULTS: The study accrued 30 patients with 32 lesions at 2 centers in the United States between June 2021 and June 2023. All patients had 1 lesion except for 2 with 2 lesions each. Target locations included lung (34.4%), adrenal gland (28.1%), lymph node (18.8%), liver (15.6%), and pancreas (3.1%). The primary objectives were met; total in-room time was
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida. Electronic address: munir@baptisthealth.net.
- Department of Radiation Oncology, Miami Cancer Institute, Miami, Florida.
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
- Office of Clinical Research, Miami Cancer Institute, Miami, Florida.
Förderung
- ViewRay Inc
Zitieren
APA
Chuong, M. D., Mittauer, K. E., Bassetti, M. F., Rojas, C., Glide-Hurst, C., Kalman, N. S., Tom, M. C., Rubens, M., Crosby, J., Burr, A., Tolakanahalli, R., Gutierrez, A. N., Bassiri, N., Mehta, M. P., & Kotecha, R. (2025). Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.03.030
Vancouver
Chuong MD, Mittauer KE, Bassetti MF, Rojas C, Glide-Hurst C, Kalman NS, et al. Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.03.030
BibTeX
@article{Chuong2025,
author = {Chuong, Michael D and Mittauer, Kathryn E and Bassetti, Michael F and Rojas, Carolina and Glide-Hurst, Carri and Kalman, Noah S and Tom, Martin C and Rubens, Muni and Crosby, Jennie and Burr, Adam and Tolakanahalli, Ranjini and Gutierrez, Alonso N and Bassiri, Nema and Mehta, Minesh P and Kotecha, Rupesh},
title = {Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2025.03.030}
}
EUVIMED